Xconomy’s Digital Events →
December 3, 2020 · New York
With the backdrop of Biogen’s BLA filing, and the FDA’s expected response for aducanumab in Alzheimer’s disease in 2020, the link between efficacy and approval seems to have broken. Conditional FDA... Read more »
From Our Editors · Podcast
Becoming the Cell & Gene Therapy Hub
Sponsored · Whitepaper
A Guide to Performing Check-ups on Pharmaceutical Distribution & Patient Access Programs
Knowing the volume of procedures and growth trends by site of care can allow you to understand the market demand for your product
© 2007-2020, Xconomy, Inc.
Xconomy is a registered service mark of Xconomy, Inc.
All rights reserved.